Literature DB >> 9193312

Severe persistent visual field constriction associated with vigabatrin. Reaction might be dose dependent.

I C Wong, G E Mawer, J W Sander.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1997        PMID： 9193312      PMCID： PMC2126862     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  16 in total

1.  Visual field defect associated with vigabatrin. Many more patients may be affected than were found in study.

Authors:  I F Comaish; C Gorman; N R Galloway
Journal:  BMJ       Date:  2000-05-20

2.  Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin.

Authors:  P Hardus; W M Verduin; G Postma; J S Stilma; T T Berendschot; C W van Veelen
Journal:  Br J Ophthalmol       Date:  2000-07       Impact factor: 4.638

3.  Vigabatrin and retinal changes.

Authors:  Hanne Jensen; Ole Sjö; Peter Uldall; Lennart Gram
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

4.  Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers.

Authors:  I Nousiainen; R Kälviäinen; M Mäntyjärvi
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

5.  Mortality rates and causes of death in children with epilepsy prescribed antiepileptic drugs: a retrospective cohort study using the UK General Practice Research Database.

Authors:  Ruth Ackers; Frank M C Besag; Elaine Hughes; Waney Squier; Macey L Murray; Ian C K Wong
Journal:  Drug Saf       Date:  2011-05-01       Impact factor: 5.606

Review 6.  A risk-benefit assessment of treatments for infantile spasms.

Authors:  R Nabbout
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

7.  Electroretinogram changes in a pediatric population with epilepsy: is vigabatrin acting alone?

Authors:  Bláthnaid McCoy; Thomas Wright; Shelly Weiss; Cristina Go; Carol A Westall
Journal:  J Child Neurol       Date:  2011-02-22       Impact factor: 1.987

Review 8.  Vigabatrin.

Authors:  James W Wheless; R Eugene Ramsay; Stephen D Collins
Journal:  Neurotherapeutics       Date:  2007-01       Impact factor: 7.620

9.  Visual field constriction and electrophysiological changes associated with vigabatrin.

Authors:  Dorothea Besch; Anne Kurtenbach; Eckart Apfelstedt-Sylla; Bettina Sadowski; Dieter Dennig; Christiane Asenbauer; Eberhart Zrenner; Ulrich Schiefer
Journal:  Doc Ophthalmol       Date:  2002-03       Impact factor: 2.379

10.  Visual field defects in pediatric patients on vigabatrin monotherapy.

Authors:  Francisco J Ascaso; María J Lopez; José A Mauri; José A Cristobal
Journal:  Doc Ophthalmol       Date:  2003-09       Impact factor: 2.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.